|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.61 USD | +3.57% |
|
+3.98% | -10.00% |
| 05-15 | Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents | CI |
| 05-14 | William Blair Upgrades Neuronetics to Outperform From Market Perform | MT |
Neuronetics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was USD 17.42 million compared to USD 15.54 million a year ago. Net loss was USD 7.87 million compared to USD 10.52 million a year ago.
Basic loss per share from continuing operations was USD 0.27 compared to USD 0.38 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to USD 0.38 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -10.00% | 78.23M | |
| +12.15% | 227B | |
| +14.90% | 197B | |
| +18.22% | 141B | |
| +29.15% | 110B | |
| +0.53% | 64.15B | |
| +16.92% | 53.72B | |
| +6.33% | 51.75B | |
| +10.93% | 45.2B | |
| +5.87% | 37.37B |
NEURONETICS, INC. 
